Current treatment options for chronic granulomatous disease

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 7, 2002, Pages 857-863

  Goldblatt, David ^a  

^a NATIONAL HEALTH SERVICE   (United Kingdom)

Author keywords

Bone marrow transplantation; Gene therapy; Interferon ; Itraconazole; NADPH oxidase; Neutrophil; Phagocytes; Trimethoprim sulfamethoxazole; Voriconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; ITRACONAZOLE; MONOCLONAL ANTIBODY; POSACONAZOLE; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID; TERBINAFINE; THALIDOMIDE; THYMOCYTE ANTIBODY; TRIAZOLE DERIVATIVE; VORICONAZOLE; ANTIINFECTIVE AGENT; IMMUNOLOGICAL ADJUVANT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; BACTERIAL INFECTION; CHRONIC GRANULOMATOUS DISEASE; COLITIS; CONTROLLED STUDY; DERMATOMYCOSIS; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; GRANULOCYTE TRANSFUSION; HUMAN; MYCOSIS; REVIEW; BONE MARROW TRANSPLANTATION; GENE THERAPY; GRANULOCYTE; LEUKOCYTE TRANSFUSION; MORTALITY; SURVIVAL RATE; TRANSPLANTATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBIOTICS; ANTIFUNGAL AGENTS; BONE MARROW TRANSPLANTATION; COLITIS; GENE THERAPY; GRANULOCYTES; GRANULOMATOUS DISEASE, CHRONIC; HUMAN; LEUKOCYTE TRANSFUSION; SURVIVAL RATE; ANTI-BACTERIAL AGENTS; HUMANS;

EID: 0035987569     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.7.857     Document Type: Review

References (80)

1. Mutations in the X-linked and autosomal recessive forms of chronic granulomatous disease
2. An improved nitroblue tetrazolium test using phorbol myristate acetate-coated coverslips
3. A new flow cytometric assay for the evaluation of phagocytosis and the oxidative burst in whole blood
4. phox gene: Genomic organization and restriction fragment length polymorphism analysis for prenatal diagnosis in chronic granulomatous disease
5. Follow up of patients with chronic granulomatous disease diagnosed since 1990
6. Chronic granulomatous disease in adults
7. Chronic granulomatous disease (CGD): Incidence of infections and complications in 39 patients
8. Prepubertal periodontitis associated with chronic granulomatous disease
9. Colitis in chronic granulomatous disease resembling Crohn's disease: Comparative analysis of CD68-positive cells between two disease entities
10. Chronic granulomatous disease. Report on a national registry of 368 patients
11. Pericardial effusions in two boys with chronic granulomatous disease
12. Chorioretinal lesions in patients and carriers of chronic granulomatous disease
13. Long-term follow-up and outcome of 39 patients with chronic granulomatous disease
14. Burkholderia pseudomallei infection in a Puerto Rican patient with chronic granulomatous disease: Case report and review of occurrences in the Americas
15. Aspergillus nidulans infection in chronic granulomatous disease
16. Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease
17. Disseminated infection due to Chrysosporium zonatum in a patient with chronic granulomatous disease and review of non-Aspergillus fungal infections in patients with this disease
18. Chronic granulomatous disease: Mode of action of sulfamethoxazole/trimethoprim
19. Chronic granulomatous disease: Effect of sulfamethoxazole/trimethoprim on neutrophil microbicidal function
20. Activity of antibiotics in chronic granulomatous disease leukocytes
21. Continuous therapy with sulfamethoxazole-trimethoprim in patients with chronic granulomatous disease
22. Treatment of seven cases of chronic granulomatous disease with sulfamethoxazole-trimethoprim
23. Incidence, severity, and prevention of infections in chronic granulomatous disease
24. Trimethoprim sulfamethoxazole prophylaxis in the management of chronic granulomatous disease
25. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease
26. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial comparing amphotericin B
27. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients
28. European experience with oral solution and intravenous itraconazole
29. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma
30. Interferon-gamma improves splicing efficiency of CYBB gene transcripts in an interferon-responsive variant of chronic granulomatous disease due to a splice site consensus region mutation
31. Improved superoxide-generating ability by interferon gamma due to splicing pattern change of transcripts in neutrophils from patients with a splice site mutation in CYBB gene
32. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease
33. Granulocyte-macrophage colony stimulating factor does not improve neutrophil oxidative metabolism in a patient with variant X-linked chronic granulomatous disease
34. Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease: Evidence against enhanced neutrophil oxidase activity
35. Interferon gamma for chronic granulomatous disease
36. Recombinant human interferon-gamma in patients with chronic granulomatous disease - European follow up study
37. Interferon-gamma in the treatment of the chronic granulomatous diseases of childhood
38. Gamma interferon treatment of patients with chronic granulomatous disease is associated with augmented production of nitric oxide by polymorphonuclear neutrophils
39. Intraphagocytic killing of Gram-positive bacteria by ciprofloxacin
40. 2-dependent bactericidal mechanisms
41. Nocardia farcinica pneumonia in chronic granulomatous disease
42. Disseminated nocardiosis in a patient with X-linked chronic granulomatous disease and human immunodeficiency virus infection
43. Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B
44. Aspergillus osteomyelitis in chronic granulomatous disease: Treatment with recombinant gamma-interferon and itraconazole
45. Successful treatment of invasive pulmonary aspergillosis in chronic granulomatous disease with orally administered itraconazole suspension
46. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS
47. Control of proven pulmonary and suspected CNS Aspergillus infection with itraconazole in a patient with chronic granulomatous disease
48. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species
49. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium species
50. Combination therapy with caspofungin and amphotericin B lipid complex
51. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
52. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
53. Successful interferon-gamma therapy in a chronic granulomatous disease (CGD) patient suffering from Staphylococcus aureus hepatic abscess and invasive Candida albicans infection
54. Effectiveness of IFN-gamma for liver abscesses in chronic granulomatous disease
55. phox-deficient chronic granulomatous disease
56. Successful treatment of Aspergillus brain abscess with itraconazole and interferon-gamma in a patient with chronic granulomatous disease
57. Reconstitution of bactericidal activity in chronic granulomatous disease cells by glucose-oxidase-containing liposomes
58. Clinical perspectives of granulocyte transfusions: Efficacy to date
59. The white cells: Use of granulocyte transfusions
60. Greater omentum flaps and granulocyte transfusions as combined therapy of liver abscess in chronic granulomatous disease
61. Treatment with intralesional granulocyte instillations and interferon-gamma for a patient with chronic granulomatous disease and multiple hepatic abscesses
62. The use of G-CSF in normal neutrophil donors
63. Alloimmunization after granulocyte transfusions
64. Colitis in chronic granulomatous disease
65. Treatment of intractable gastrointestinal manifestations of chronic granulomatous disease with cyclosporine
66. Gastrointestinal complications of chronic granulomatous disease: Case report and literature review
67. Thalidomide enhances superoxide anion release from human polymorphonuclear and mononuclear leukocytes
68. Treatment of enteritis in chronic granulomatous disease with granulocyte colony stimulating factor
69. Infliximab for the treatment of fistulas in patients with Crohn's disease
70. Corticosteroids in treatment of obstructive lesions of chronic granulomatous disease
71. Steroid-responsive esophageal obstruction in a child with chronic granulomatous disease (CGD)
72. Corticosteroids in the management of cystitis secondary to chronic granulomatous disease
73. Prognosis of chronic granulomatous disease
74. Chronic granulomatous disease in Japan: Incidence and natural history. The study group of phagocyte disorders of Japan
75. Bone marrow transplantation for chronic granulomatous disease: Long-term follow-up and review of literature
76. Treatment of chronic granulomatous disease with nonmyoablative conditioning and a T-cell-depleted hematopoietic allograft
77. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
78. phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease
79. phox-deficient model of chronic granulomatous disease
80. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease